References
- Health Sciences Authority. Regulatory overview of therapeutic products. Available from: https://www.hsa.gov.sg/therapeutic-products/overview. Accessed April 10, 2020.
- UNESCO Institute for Statistics. Science, Technology and Innovation. Available from: http://data.uis.unesco.org/#. Accessed June 10, 2020.
- Xu X, Zhang L, Chen L, Wei F. Does COVID-2019 have an impact on the purchase intention of commercial long-term care insurance among the elderly in China? Healthcare. 2020;8(2):126.
- Xu X, Chen L. Projection of long-term care costs in china, 2020–2050: based on the bayesian quantile regression method. Sustainability. 2019;11:3530. doi:10.3390/su11133530
- Xu X, Huang X, Zhang X, Chen L. Family economic burden of elderly chronic diseases: evidence from China. Healthcare. 2019;7:99. doi:10.3390/healthcare7030099
- Chen L, Zhang X, Xu X. Health insurance and long-term care services for the disabled elderly in china: based on charls data. Risk Manag Healthc Policy. 2020;13:155–162. doi:10.2147/RMHP.S233949
- DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development cost. J Health Econ. 2003;22:151–185. doi:10.1016/S0167-6296(02)00126-1
- Xu X, Xu Z, Chen L, Li C. How does industrial waste gas emission affect health care expenditure in different regions of china: an application of bayesian quantile regression. Int J Environ Res Public Health. 2019;16(15):2748. doi:10.3390/ijerph16152748
- Daemmrich A, Mohanty A. Healthcare reform in the United States and China: pharmaceutical market implications. J Pharm Policy Pract. 2014;7(1):1–13. doi:10.1186/2052-3211-7-9
- World Bank. World development indicators. Available from: http://wdi.worldbank.org/tables. Accessed April 10, 2020.
- World Bank. Indonesia – Supporting Primary Healthcare Reform Project: Technical Assessment (English). Washington DC: World Bank Group; 2018.
- WHO SEARO. The Republic of Indonesia Health System Review. New Delhi: WHO; 2017.
- Institute for Scientific Information. The Annual G20 Scorecard research Performance 2019. Available from: https://clarivate.com/webofsciencegroup/campaigns/the-annual-g20-scorecard-research-performance-2019/. Accessed April 5, 2020.
- Han E, Chae SM, Kim NS, Park S. Effects of pharmaceutical cost containment policies on doctors’ prescribing behavior: focus on antibiotics. Health Policy (New York). 2015;119(9):1245–1254. doi:10.1016/j.healthpol.2015.05.005
- Bae G, Park C, Lee H, Han E, Kim DS, Jang S. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea. BMC Health Serv Res. 2014;14:100. doi:10.1186/1472-6963-14-100
- Cho MH, Yoo KB, Lee HY, et al. The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea. Health Policy (New York). 2015;119(5):604–611. doi:10.1016/j.healthpol.2015.01.002
- Ministry of Health, Republic of Indonesia. Strategic plan 20202024. Available from: https://www.kemkes.go.id/resources/download/info-terkini/Rakerkesnas-2020/. Accessed March 30, 2020.
- Boer FP. The Valuation of Technology: Business and Financial Issues in R&D, Operations Management Series for Professionals. New York: John Wiley; 1999.
- CNN Indonesia. Indonesia Research Budget; 2020. Available from: https://www.cnnindonesia.com/teknologi/20200128122325-199-469363/anggaran-riset-dan-pengabdian-masyarakat-2020-capai-rp146-t. Accessed April 10, 2020.
- Jayasundara K, Hollis A, Krahn M, et al. Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet J Rare Dis. 2019;14(1):12. doi:10.1186/s13023-018-0990-4
- Jakovljevic MB. BRIC’s growing share of global health spending and their diverging pathways. Front Public Health. 2015;3:135. doi:10.3389/fpubh.2015.00135
- Jakovljevic M, Getzen TE. Growth of global health spending share in low and middle income countries. Front Pharmacol. 2016;7:21. doi:10.3389/fphar.2016.00021
- Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. Lancet. 2017;389:403–476. doi:10.1016/S0140-6736(16)31599-9
- Wagner AK, Graves AJ, Reiss SK, et al. Access to care and medicines, burden of health care expenditures, and risk protection: results from the world health survey. Health Policy (New York). 2011;100:151–158. doi:10.1016/j.healthpol.2010.08.004
- Hill AM, Barber MJ, Gotham D. Estimated costs of production and potential prices for the WHO essential medicines list. BMJ Glob Health. 2018;3:e000571. doi:10.1136/bmjgh-2017-000571
- Fortunak JM, de Souza RO, Kulkarni AA, et al. Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey. Antivir Ther. 2014;19(Suppl 3):15–29. doi:10.3851/IMP2897
- Basu P, Joglekar G, Rai S, et al. Analysis of manufacturing costs in pharmaceutical companies. J Pharm Innov. 2008;3:30–40. doi:10.1007/s12247-008-9024-4
- World Health Organization. The world medicines situation. Available from: http://apps.who.int/medicinedocs/pdf/s6160e/s6160e.pdf. Accessed March 2, 2020.
- UN Secretary-General. The United Nations secretary-general’s high-level panel on access to medicines report: promoting innovation and access to health technologies; [cited 2020 April 1]. Available from: http://www. unsgaccessmeds.org/s/UNSG- HLP- Report- FINAL- 12- Sept- 2016. Pdf. Accessed April 2, 2020.
- The Jakarta Post. Pharma companies still dependent on imported APIs, says ministry. Available from: https://www.thejakartapost.com/news/2018/10/18/pharma-companies-still-dependent-on-imported-apis-says-ministry.html. Accessed April 2, 2020.
- Indonesia Investments. Pharmaceutical Exports Indonesia Remain Under Pressure in 2017. Available from: https://www.indonesia-investments.com/business/business-columns/pharmaceutical-exports-indonesia-remain-under-pressure-in-2017/item7867. Accessed April 2, 2020.
- Simanjuntak DG, Tjandrawinata RR. A study on influencers of total sales revenue of generic pharmaceutical companies in Indonesia. MPRA. 2011. 31628:111. Available from: https://mpra.ub.uni-muenchen.de/31628/. Accessed September 4, 2020.
- LEAD Innovation Management. The 4 phases of innovation. Available from: https://www.lead-innovation.com/english-blog/the-4-phases-of-innovation. Accessed April 2, 2020.
- DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33. doi:10.1016/j.jhealeco.2016.01.012
- International Federation of Pharmaceutical Manufacturers & Associations. The pharmaceutical industry and global health, facts and figures 2017. Available from: https://www.ifpma.org/wp-content/uploads/2017/02/IFPMA-Facts-And-Figures-2017.pdf. Accessed April 5, 2020.
- Carayannis EG, Campbell DFJ. ‘Mode 3ʹ and ‘quadruple helix’: toward a 21st century fractal innovation ecosystem. Int J Technol Manage. 2009;46(3/4):201–234. doi:10.1504/IJTM.2009.023374
- Armas EB, Osorio CG, Moreno-Dodson B, Abriningrum DE. Agriculture public spending and growth in indonesia. Policy research working paper; no. WPS 5977. World Bank. 2012.Available from: https://openknowledge.worldbank.org/handle/10986/3263. Accessed September 4, 2020.
- Siagian RC, Ayuningtyas D. Gap analysis for drug development policy-making: an attempt to close the gap between policy and its implementation. PLoS One. 2019;14(8):e0220605. doi:10.1371/journal.pone.0220605
- Rottingen JA, Regmi S, Eide M, et al. Mapping of available health research and development data: what’s there, what’s missing, and what role is there for a global observatory? Lancet. 2013;382:1286–1307. doi:10.1016/S0140-6736(13)61046-6
- WHO. Research and development to meet health needs in developing countries: strengthening global financing and coordination. Available from: https://apps.who.int/iris/bitstream/handle/10665/254706/9789241503457-eng.pdf;jsessionid=D7D1D78319B6D54CD9AFAE78FA5DCECD?sequence=1. Accessed September 4, 2020.
- Cole CB, Trolle S, Edwards DJ. Developing the latest framework to measure and incentivise pharmaceutical industry contributions to health research and development. Health Res Policy Syst. 2018;16(1):73. doi:10.1186/s12961-018-0332-y
- Leydesdorff L The knowledge-based economy and the triple helix model. Available from: https://www.leydesdorff.net/arist09/arist09.pdf. Accessed April 2, 2020.
- WHO. Country Pharmaceutical Situations, Fact Book on WHO Level 1 Indicators 2007. Geneve: WHO; 2009.
- Suwantika AA, Postma MJ. Effect of breastfeeding promotion interventions on cost-effectiveness of rotavirus immunization in Indonesia. BMC Public Health. 2013;13(1):1106. doi:10.1186/1471-2458-13-1106
- Jakovljevic MB, Milovanovic O. Growing burden of non-communicable diseases in the emerging health markets: the case of BRICS. Front Public Health. 2015;3:65. doi:10.3389/fpubh.2015.00065
- Jakovljevic M, Jakab M, Gerdtham U, et al. Comparative financing analysis and political economy of noncommunicable diseases. J Med Econ. 2019;22(8):722–727. doi:10.1080/13696998.2019.1600523
- Morel CM, Acharya T, Broun D, et al. Health innovation networks to help developing countries address neglected diseases. Science. 2005;309(5733):401–404. doi:10.1126/science.1115538
- Jakovljevic M, Groot M, Souliotis K. Editorial: health care financing and affordability in the emerging global markets. Front Public Health. 2016;4:2.
- Jakovljevic MM. Comparison of historical medical spending patterns among the BRICS and G7. J Med Econ. 2016;19(1):70–76. doi:10.3111/13696998.2015.1093493
- Jakovljevic M, Timofeyev Y, Ekkert NV, et al. The impact of health expenditures on public health in BRICS nations. J Sport Health Sci. 2019;8(6):516–519. doi:10.1016/j.jshs.2019.09.002